An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, phase 3 ARANOTE trial.

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

FDA approves Bayer's Nubeqa with ADT for metastatic hormone-sensitive prostate cancer, cutting death risk by 46%. Read more ...

ProstaVive is a male health supplement that has been receiving much attention lately because it is said to address the ...

Prostate cancer affects over 230,000 men each year, said KOAT health expert Dr. Abinash Achrekar, a University of New Mexico ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...

A study led by Cancer Center at Illinois (CCIL) member Jason Ridlon, associate professor of animal sciences in the College of ...

ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

An AI test boosts cure chances for prostate cancer by predicting who benefits from abiraterone, reducing side effects and ...